The Scottish Medicines Consortium (SMC) has today (13 January) announced that brentuximab vedotin (brand name Adcetris®) will be available on the NHS in Scotland for adults with certain advanced T-cell skin lymphomas who have not responded (refractory) or whose lymphoma has come back (relapsed) after at least one previous systemic (whole body) treatment. This includes people with:
- mycosis fungoides that is stage 2B or above
- primary cutaneous anaplastic large cell lymphoma
- Sézary syndrome.
Brentuximab vedotin is only suitable for people who have had lab tests that show their lymphoma cells make a protein called CD30 (known as ‘CD30-positive’ or ‘CD30+’ lymphoma).
Brentuximab vedotin is a type of targeted therapy called an antibody–drug conjugate. This is an antibody joined to a chemotherapy drug. The antibody sticks to CD30 on lymphoma cells and delivers the chemotherapy directly to them.
Brentuximab vedotin is already available on the NHS in England and Wales for adults with advanced CD30-positive T-cell skin lymphoma who have had at least one previous systemic treatment.
For more information about new drugs being developed to treat lymphoma, visit Lymphoma TrialsLink.
13 January 2019